SQ-LIP-000016 · v1.0 (archived) · View current version →
Is gestrinone an effective treatment for lipedema?
There is no evidence either way. A systematic (PRISMA) review found no clinical trials, observational studies or case reports evaluating gestrinone for lipedema, so its effectiveness and safety are simply unknown — this is an absence of evidence, not evidence that it is ineffective. Because nothing supports it, off-label use (particularly as subcutaneous implants) is not justified, and the safety of that route is unstudied.
Knowledge freshness = share of the 1 indexed evidence sources from the last 5 years (newest 2025, oldest 2025) . Low freshness flags an ageing evidence base — not that the answer is wrong.
Evidence over time
supporting contradicting refining / context Each dot is a study, placed by year and coloured by whether the linked claim supports or contradicts the answer. As the surveillance loop runs, claim revisions and new evidence will extend this timeline.
Choose a format (Vancouver default). Citing a version captures the evidence state on that date; this page shows the current version — see version history.
What changed in this version
Initial version (v1.0): 1 founding claims indexed from the lipedema pilot. The automated surveillance loop (new-article ingestion → supports / contradicts / refines) has not yet run.
Supporting claims
- None indexed yet.
Contradictory claims
- SCR-LIP-000040 contradicting
There is no scientific evidence supporting gestrinone for lipedema: a PRISMA systematic review identified zero clinical trials, observational studies or case reports evaluating it, particularly as subcutaneous implants.
DOI:10.7759/cureus.97213
Major uncertainty
Absence of evidence rather than evidence of absence; safety of the implant route is unstudied.
Version history
- SQ-LIP-000016 · v1.0 — 2026-05-30 — founding index (1 claims) · view this version